ReviewFrontiers in immunology2025
Extracellular vesicles in osteoarthritis: mechanisms, therapeutic potential, and diagnostic applications.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Nanoimmunomodulation for cartilage repair in osteoarthritis: reprogramming the inflammatory joint microenvironment.International journal of pharmaceutics: X · 2026Review
- Mesenchymal Stem Cell-Lysate Sustained-Release Nano-Hydrogel Alleviates Spinal Cord Injury by Inhibiting Ferroptosis and Mitochondrial Intrinsic Apoptosis.International dental journal · 2026Article
- Mesenchymal stromal cells therapy for remodeling the joint microenvironment: mechanisms, nanotechnology-enhanced strategies, and translation prospects.Stem cell research & therapy · 2026Review
- Extracellular Vesicles in Osteoarthritis: From Pathogenic Mediators to Engineered Therapeutics in a Precision Medicine Roadmap.Journal of extracellular biology · 2026Review
- Exosomes and Small Extracellular Vesicles as an Alternative to Mesenchymal Stromal Cell Therapy in Knee Osteoarthritis: From Biological Rationale to Clinical Evidence.International journal of molecular sciences · 2026Review
- The role of neutrophils in the pathophysiology of knee osteoarthritis : a review.Bone & joint research · 2026Article
- Deciduous pulp stem cell-derived extracellular vesicles stimulate the proliferation of cartilage progenitor cells via extracellular signal-regulated protein kinase 1/2 activation.Scientific reports · 2026Article
- Anti-Inflammatory and Angiogenic Effects of Stem Cell Secretome.International journal of molecular sciences · 2026Article
- Extracellular vesicle-mediated immunomodulation and targeted delivery: breakthroughs and challenges in rheumatoid arthritis therapy.Frontiers in immunology · 2026Review
- Mammalian cell-derived extracellular vesicles remodel the immune-repair microenvironment in osteoarthritis: from pathological signal transmission to regenerative therapy.Frontiers in immunology · 2026Review
- Translating Osteoarthritis Genetic Risk Into Biomarkers: Opportunities, Pitfalls, and Implementation Considerations.Human mutation · 2026Review
- Epigenetic regulation in osteoarthritis: recent updates and emerging mechanisms.Frontiers in genetics · 2026Review
- Exploration of acetylation-related biomarkers in osteoarthritis through bioinformatics analysis.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a chronic joint disease characterized by cartilage degradation, inflammation, and bone structural changes, leading to significant disability. Current therapeutic strategies, including traditional treatments and stem cell-based therapies, face limitations such as inability to prevent disease progression, immunogenic rejection, and tumorigenic risks. Extracellular vesicle (EVs), nanoscale membrane-bound vesicles secreted by cells, has emerged as a promising cell-free therapeutic approach due to their low immunogenicity, stability, and ability to mediate intercellular communication. This review summarizes the roles of EVs derived from various cell types, including cartilage progenitor cells (CPCs), bone marrow mesenchymal stem cells (BMSCs), synovial mesenchymal stem cells (SMSCs), adipose-derived stem cells (ADSCs), and immune cells, in OA pathogenesis and treatment. EVs exhibit multifaceted therapeutic potential, including immunomodulation, chondrocyte regeneration, and anti-inflammatory effects. Additionally, EVs serve as diagnostic biomarkers, offering non-invasive early detection of OA. Despite their promise, challenges such as scalability, targeting efficiency, and safety concerns remain. This review highlights the potential of EVs as both therapeutic agents and diagnostic tools, paving the way for innovative OA management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.